Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report

​Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life Sciences, Inc. (NASDAQ:CAI) announced that it is adding a new AI-powered “breast cancer signature” to its Caris Molecular Tumor Board Report. The report is a research tool that doctors and researchers use for additional tumor biology resources and can be ordered with the company’s MI Cancer Seek.

​Management noted that the report will now include a “Caris AI Insights” section with signatures powered by artificial intelligence. These signatures help in predicting how HER2-negative breast cancer patients will respond to capecitabine as first-line treatment. The AI has been trained on data from more than 2,000 gene expression and includes features from patients’ Whole Exome Sequencing and Whole Transcriptome Sequencing. Moreover, these signatures can also assist in identifying tissue of origin, assessing metastasis risk, and guiding personalized treatment strategies for patients.

MI Cancer Seek was approved by the FDA in November 2024 as the first tissue-based test combining Whole Exome Sequencing and Whole Transcriptome Sequencing for solid tumors.

​Caris Life Sciences, Inc. (NASDAQ:CAI) is an artificial intelligence TechBio company that provides molecular profiling services and develops solutions using molecular information and machine learning algorithms in the United States and internationally.